
Please try another search
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Name | Age | Since | Title |
---|---|---|---|
Paul A. Wagner | 54 | 2017 | CEO, President & Chairman |
Barbara K. Finck | 77 | 2022 | Chief Medical Clinician & Director |
Shivpreet Singh Kapoor | - | 2024 | Director |
Patricia S. Walker | 66 | 2020 | Member of Scientific Advisory Board |
David W. Gryska | 70 | 2023 | Independent Director |
Richard G. Vincent | 61 | 2024 | Independent Director |
Steven Kornfeld | 57 | 2020 | Independent Director |
Scott C. Brun | 56 | 2022 | Independent Director |
Stephen K. Doberstein | 66 | 2022 | Member of Scientific Advisory Board & Independent Director |
Shivpreet Kapoor | 49 | 2024 | Independent Director |
Lawrence F. Eichenfield | 66 | 2020 | Chair of Scientific Advisory Board |
Eric Simpson | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review